Primary regulatory
FDA Approves Mounjaro (Tirzepatide) for Type 2 Diabetes
FDA approval of Mounjaro (tirzepatide) injection for Type 2 diabetes, NDA 215866.
U.S. Food and Drug AdministrationPublished 2022-05-13Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-mounjaro-approval-2022
Source usage
Linked from 10 pages
Compound
Tirzepatide
ComparisonRetatrutide vs Tirzepatide
ComparisonTirzepatide vs Semaglutide
Evidence curationBest Peptides for Weight Loss
GuideCompounded GLP-1 Regulation: What Changed and What to Check
GuideFDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
GuidePeptide Terminology Glossary
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.